MNG946
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.312
- UV_RESPONSE_DN+0.289
- ANGIOGENESIS+0.249
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.245
- WNT_BETA_CATENIN_SIGNALING+0.241
- NOTCH_SIGNALING+0.210
- PROTEIN_SECRETION+0.159
- TGF_BETA_SIGNALING+0.148
- APICAL_SURFACE+0.098
- BILE_ACID_METABOLISM+0.085
Top 10 suppressed
- MYC_TARGETS_V2-0.497
- OXIDATIVE_PHOSPHORYLATION-0.472
- TNFA_SIGNALING_VIA_NFKB-0.455
- CHOLESTEROL_HOMEOSTASIS-0.401
- MTORC1_SIGNALING-0.390
- UV_RESPONSE_UP-0.368
- MYC_TARGETS_V1-0.367
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.317
- IL6_JAK_STAT3_SIGNALING-0.314
- GLYCOLYSIS-0.309
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X84315f98.9366.4174.be54.3cdd1fd9db07 | — | cohortA1 | 0.830 |
| 2 | TCGA-QK-A8Z9-01B-11R-A39I-07 | — | — | 0.784 |
| 3 | TCGA-CN-5361-01A-01R-1436-07 | — | — | 0.783 |
| 4 | 65f86d9a-828b-4e8b-a656-38baba5a54f7 | — | — | 0.778 |
| 5 | SRR1313107 | — | F | 0.778 |
| 6 | TCGA-44-6147-01A-11R-1755-07 | — | cohortA1 | 0.771 |
| 7 | d7bbb44a-3fe0-4455-99d0-90be213f2a31 | — | — | 0.768 |
| 8 | SRR1319158 | GTEX | — | 0.767 |
| 9 | 4f0b1ac0-c503-4852-9a44-cb4231f4b17b | — | — | 0.766 |
| 10 | SRR29022838 | — | A | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.312 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.289 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.249 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.245 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.241 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.159 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.148 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.098 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.085 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.075 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.071 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.069 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.041 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.014 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.004 | Idelalisib | — uncovered |